Introduction
There are increasing lines of evidence supporting the hypothesis that atherosclerosis is an inflammatory disease (1) . During the onset of atherosclerosis, vascular smooth muscle cells (VSMCs) undergo phenotypic changes, switching from a contractile phenotype to a proliferating and secretory phenotype. Early atherosclerotic lesions have many characteristics in common with the inflammatory reaction, and VSMCs participate in the local inflammatory process involved in the development of lesions and neointimal formation. Activation of inflammatory cells leads to massive release of proinflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-α. In VSMCs, IL-1β not only induces extion of NO with the superoxide anion. Therefore, regulation of iNOS gene expression has also been implicated in the pathogenesis of vascular remodeling and atherosclerosis (8) (9) (10) (11) . Recently, the significance of iNOS in the pathogenesis of atherosclerosis was demonstrated by studies of genetic deficiency of iNOS in apo E-gene deficient mice (12) .
In various inflammatory conditions, lipoxygenase (LOX) and secretory phospholipase A2 (sPLA2), as well as iNOS, are induced in vascular and/or mononuclear cells (13, 14) . LOX products, such as 12(S)-hydroxyeicosatetraenoic acid (HETE), stimulate the proliferation of VSMCs and fibronectin gene expression (15) and mediate oxidative modification of low density lipoprotein (LDL) (16) . In addition, LOX enzymes have been shown to be expressed in macrophage-rich areas of atherosclerotic lesions (17) . A recent study has indicated that 12-LOX is expressed in the vascular tissue of diabetic atherosclerosis (18) . Furthermore, targeted disruption of the 12-LOX gene diminishes atherosclerosis in apo E-gene deficient mice (19) . sPLA2 is the key enzyme for the release of membrane-derived arachidonic acid (AA), which is an important substrate for LOX.
These lines of evidence strongly suggest that iNOS, sPLA2, and LOX play important roles in producing vascular inflammation and thereby accelerating atherosclerosis. At the present time, however, it is not entirely clear whether arachidonate pathways and the NO-producing system regulate each other mutually. The aim of the present study was to investigate the regulatory mechanisms of stimulus-induced NO production and iNOS expression by the PLA2-LOX pathway.
Methods

Materials
Dulbecco's modified Eagle medium (D-MEM), fatal bovine serum (FBS) and trypsin were obtained from GIBCO BRL (Gaithersburg, USA). Rat recombinant IL-1β was purchased from R&D Systems (Minneapolis, USA). ONO-RS-082 and AACOCF3 were from Biomol (Plymouth Meeting, USA), nordihydroguaiaretic acid (NDGA) and indomethacin were from Sigma Chemicals (St. Louis, USA), and baicalein was from Aldrich Chemical (Milwaukee, USA). Various eicosanoids, NS-398 and REV5901 were from Cayman Chemicals (Ann Arbor, USA).
Cell Cultures
VSMCs from the thoracic aorta of 4-week-old male Wistar rats were prepared by the explant method and cultured in D-MEM medium containing 10% FBS at 37 ºC in a humidified atmosphere of 95% air and 5% CO2 as described previously (20) . The cells were studied up to the ninth passage. Confluent VSMCs were incubated in phenol red-free test medium for 24 h before the experiments. They were then incubated in the test medium containing IL-1β (10 ng/ml) with or without LOX inhibitor (NDGA, baicalein), or COX inhibitor (indomethacin, NS-398) for 24 h. Phospholipase A2 (PLA2) inhibitor (ONO-RS-082, AACOCF3) or 5-LOX inhibitor (REV5901) was added 1 h prior to treatment with IL-1β. A range of concentrations for all inhibitors was tested for efficacy and cell toxicity.
The experiments were performed under the guidelines for animal experiments set by the Animal Experiment Committee of Yokohama City University School of Medicine.
Nitrite Analysis
The levels of nitrite, a stable metabolite of NO, in the medium were used as an index of NO production (21) (22) (23) . The medium was mixed with an equal volume of Griess reagent containing 1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 2% phosphoric acid for 10 min. The absorbance at 540 nm was measured in duplicate with a 96-well plate reader (Immunoreader; Intermed, Tokyo, Japan), and the nitrite concentration was determined using a calibration curve with sodium nitrite standards. Background nitrite levels were subtracted from sample values. ONO-RS-082, AACOCF3, NDGA, baicalein, indomethacin, NS-398 and REV5901 were solubilized in dimethyl sulfoxide (DMSO). Various eicosanoids were solubilized in ethanol. Because DMSO and ethanol affect nitrite analysis, equal amounts of DMSO and ethanol were added to the media for the control group to compare data under the same experimental conditions.
Western Blot Analysis
Western blot analysis was performed essentially as described in a previous study (24) . Protein was isolated from VSMCs using buffers and protease inhibitors (50 mmol/l Tris-HCl pH 8.0, 2 mmol/l ethyleneglycol bis (2-aminoethyl-ether) tetraacetic acid (EGTA), 10 µmol/l phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml leupeptin, 1.25 mg/ml trypsin inhibitor from chicken egg white (ETI) and 1% SDS). Protein concentration was determined by DC protein assay (BIO-RAD, Hercules, USA). Lysate protein was separated out by electrophoresis on a 6% SDS-polyacrylamide gel and then transferred to an Immobilon-P PVDF membrane (Millipore, Bedford, USA). The unoccupied protein binding sites on the membranes were blocked with 5% skim milk in PBS containing 5% BSA and 0.1% Tween 20 for 1 h at room temperature. The membranes were incubated with rabbit polyclonal antibody for 130-kilodalton iNOS protein (1:10,000; Transduction Laboratories, Lexington, USA) for 1 h at room temperature. After washing, the membranes were incubated for 20 min with anti-rabbit immunoglobulin G (IgG)-antibody conjugated with horseradish peroxidase (HRP), and exposures were performed using ECL plus (Amersham, Buckinghamshire, UK) and an FLA3000 image analyzer (Fuji Photo Film, Tokyo, Japan).
Fig. 1. Dose-dependent increase in stimulated nitrite production and iNOS protein expression in rat VSMCs. IL-1β was added at the concentration indicated and this treatment lasted 24 h. (A) Effect of IL-1β on nitrite production. The y axis is nitrite level (µmol/l). Data are the mean SEM from 3 experiments. p 0.01 vs. the IL-1β (0 ng/ml)-treated group. (B) Western blot showing the effect of IL-1β on iNOS protein expression. The y axis is the iNOS protein level expressed as a percentage of that in the IL-1β (30 ng/ml)-treated group (which is set to 100).
Fig. 2. Effect of pretreatment with the sPLA2 inhibitor ONO-RS-082 or the cPLA2 inhibitor AACOCF3 on IL-1β (10 ng/ml)-stimulated nitrite production and iNOS expression. Effect of (A) ONO-RS-082 or (B) AACOCF3 on IL-1β-stimulated nitrite production. ONO-RS-082 and AACOCF3 were added at the concentration indicated (µmol/l). The y axis is nitrite level expressed as a percentage of that in the IL-1β-treated group (which is set to 100). Data are the mean SEM from 3 experiments. p 0.01 vs. the IL-1β-treated group. (C) Western blot showing the effect of ONO-RS-082 or AACOCF3 on IL-1β-stimulated iNOS protein expression. The y axis is iNOS protein level expressed as a percentage of that in the IL-1β-treated group (which is set to 100). ONO-RS-082 or AACOCF3 alone had no effect on nitrite or iNOS levels.
Statistical Analysis
The unpaired Student's t-test was used for statistical analysis of the differences among groups. Values of p 0.05 were considered to indicate statistical significance. All quantifiable data were expressed as the mean SEM.
Results cPLA2 Inhibitor Blocks IL-1 -Stimulated Nitrite Production and iNOS Expression
IL-1β stimulated nitrite production and iNOS protein expression in a dose-dependent manner (Fig. 1) . After a 24-h incubation, nitrite concentration reached a maximum at an IL-1β concentration of 7.1 µmol/l. A submaximal concentration of IL-1β (10 ng/ml) was used for experiments.
To determine whether the PLA2 pathway is involved in IL-1β regulation of nitrite production and iNOS expression, VSMCs were treated with either the sPLA2 inhibitor ONO-RS-082 or the cPLA2 inhibitor AACOCF3 (Fig. 2) . ONO-RS-082 (1 to 10 µmol/l) produced a dose-dependent decrease in nitrite and iNOS protein levels. At the highest concentration (10 µmol/l), ONO-RS-082 reduced IL-1β-stimulated nitrite production by 75% and iNOS protein expression by 23% after 18 h of incubation. The cPLA2 inhibitor AACOCF3 (3 to 30 µmol/l) produced a slight decrease in nitrite production and iNOS protein expression at high concentration. ONO-RS-082 (1 to 10 µmol/l) or AACOCF3 (3 to 30 µmol/l) alone had no effect on nitrite or iNOS levels.
LOX Inhibitor Blocks IL-1 -Stimulated Nitrite Production and iNOS Expression
PLA2 releases AA, which is a substrate for LOX and COX, from the membrane. To determine whether the LOX pathway is involved in IL-1β regulation of nitrite production and set to 100) . NDGA or baicalein alone had no effect on nitrite or iNOS levels.
iNOS expression, VSMCs were treated with either the nonselective LOX inhibitor, NDGA, or the selective 12-LOX inhibitor, baicalein. After a 24-h incubation, NDGA produced a dose-dependent decrease in nitrite and iNOS protein levels (Fig. 3) . NDGA (10 µmol/l) reduced IL-1β-stimulated nitrite production by 67% and iNOS protein expression by 61%. Baicalein produced a slight but significant decrease in IL-1β-stimulated nitrite production at the highest concentration. This inhibitor, however, did not decrease iNOS protein expression. The 5-LOX inhibitor REV5901 (3 to 10 µmol/l) did not affect IL-1β-stimulated nitrite or iNOS protein levels (data not shown). NDGA (1 to 10 µmol/l), baicalein (3 to 30 µmol/l), or REV5901 (3 to 10 µmol/l) alone had no effect on nitrite or iNOS levels.
Because NDGA blocked IL-1β-stimulated nitrite production, we also examined the effect of LOX products on IL-1β-stimulated nitrite production. The 12-LOX product 12(S)-HETE enhanced the IL-1β-stimulated nitrite production and iNOS protein expression (Fig. 4) . On the other hand, other eicosanoids, such as 5(S)-HETE, 12(R)-HETE and 15(S)-HETE, did not affect IL-1β-stimulated nitrite production. 12(R)-HETE also did not affect IL-1β-stimulated iNOS protein expression. These eicosanoids (1 µmol/l) alone had no effect on nitrite or iNOS levels.
COX Inhibitors Have Little Effect on IL-1 -Stimulated Nitrite Production and iNOS Expression
To determine whether the cyclooxygenase (COX) pathway is involved in IL-1β regulation of nitrite production and iNOS expression, VSMCs were treated with either the non-selective COX inhibitor indomethacin or the selective COX-2 inhibitor NS-398. The indomethacin (1 to 10 µmol/l) and NS-398 (1 to 10 µmol/l) did not have any significant effect on nitrite and iNOS levels (Fig. 5) .
Discussion
The present study was designed to examine whether the enzymes PLA2, LOX and COX are involved in IL-1β-induced NO production and iNOS protein expression. PLA2, LOX and COX are components of the AA cascade. AA is a substrate for both LOX and COX. Many reports have indicated that the expressions of these enzymes are induced by vascular inflammation, and that together they play roles in the acceleration of atherosclerosis. However, the interrelated mechanisms of their involvement in VSMCs remain to be fully described. In the present study, we therefore examined the effect of several inhibitors for PLA2, LOX or COX on IL-1β-induced NO production and iNOS protein expression in VSMCs. In addition, we examined the effect of LOX products on IL-1β-induced NO production and iNOS protein expression.
Fig. 4. Effect of the exogenous eicosanoids on nitrite production and iNOS expression. Eicosanoids were added to IL-1β (10 ng/ml)-stimulated VSMCs. (A) Effect of the exogenous 5(S)-HETE (1 µmol/l), 12(S)-HETE (1 µmol/l), 12(R)-HETE (1 µmol/l) or 15(S)-HETE (1 µmol/l) on IL-1β-stimulated nitrite production. The y axis is nitrite level expressed as a percentage of that in the IL-1β-treated group (which is set to 100). Data are the mean SEM from 3 experiments. p 0.01 vs. the IL-1β treated group. 5(S)-HETE, 12(S)-HETE, 12(R)-HETE or 15(S)-HETE alone had no effect on nitrite levels. (B) Western blot showing the effect of 12(S)-HETE (1 µmol/l) or 12(R)-HETE (1 µmol/l) on IL-1β-stimulated iNOS protein expression. The y axis is iNOS protein level expressed as a percentage of that in the IL-1β-treated group (which is set to 100). 12(S)-HETE (1 µmol/l) or 12(R)-HETE (1 µmol/l) alone had no effect on iNOS levels.
As shown in Fig. 3 , the non-selective LOX inhibitor NDGA induced a significant decrease in nitrite and iNOS protein levels, suggesting that the LOX pathway plays important roles in the regulation of iNOS activity and NO production in rat VSMCs. This result is in agreement with the evidence reported previously in other cell types. Imai et al. (25) and Ryoyama et al. (26) demonstrated that LOX inhibition with NDGA reduced lipopolysaccharide (LPS)-stimulated or OK-432-stimulated nitrite production in macrophages. LaPointe and Sitkins (27) reported a similar inhibitory effect of NDGA on IL-1β-stimulated iNOS expression in neonatal ventricular myocytes. And another recent study indicates that 12-LOX can be induced by cytokines in VSMCs (14) .
Atherosclerosis is thought to be an inflammatory disease (1). iNOS expression is induced after immunological and inflammatory stimuli (3, 28) , while excess NO production by iNOS in the blood vessels causes further inflammation, cellular damage, and apoptosis. iNOS may contribute to lesion formation by increasing oxidative stress in the vessel wall (29) . Genetic deficiency of iNOS decreases Western-type diet-induced atherosclerosis in apolipoprotein E (apo E)-genedeficient mice (12) . On the other hand, the sPLA2 and LOX enzymes also can be induced by inflammatory cytokines. In particular, 12-LOX is known to be expressed in atherosclerotic lesions (18) and to play a key role in the pathogenesis of accelerated vascular disease. A pharmacological LOX inhibitor or specific molecular LOX inhibitor, such as the 12-LOX ribozyme, could significantly reduce the extent of neointimal thickening in balloon-injured rat carotid arteries (30, 31) . The direct in vivo significance of 12-LOX activation in atherosclerosis was recently demonstrated in a study in which 12-LOX gene deficiency dramatically reduced lesion development in apo E-deficient mice (19) . Hence, therapeutic strategies targeting iNOS expression or 12-LOX activity could help in the treatment of atherosclerosis. Although further studies will be needed to determine whether LOX products actually regulate cytokine-induced NO production in vivo, we here demonstrated that LOX products
Fig. 5. Effect of the non-selective COX inhibitor indomethacin or selective COX-2 inhibitor NS-398 on IL-1β (10 ng/ml)-stimulated nitrite production and iNOS expression. Effect of (A) indomethacin or (B) NS-398 on IL-1β-stimulated nitrite production. Indomethacin and NS-398 were added at the concentration indicated (µmol/l). The y axis is nitrite level expressed as a percentage of that in the IL-1β-treated group (which is set to 100). Data are the mean SEM from 3 experiments. p 0.01 vs. the IL-1β-treated group. (C) Western blot showing the effect of indomethacin or NS-398 on IL-1β-stimulated iNOS protein expression. The y axis is iNOS protein level expressed as a percentage of that in the IL-1β-treated group (which is set to 100). Indomethacin or NS-398 alone had no effect on nitrite or iNOS levels.
may contribute to the enhancement of cytokine-induced iNOS production in inflammatory lesions of the artery, and thereby to the acceleration of lesion formation.
Several types of LOX enzymes are known to be involved in the pathway. In the present study, baicalein, a selective 12-LOX inhibitor, was found to produce a significant decrease in nitrite levels. This result was compatible with our finding that 12(S)-HETE enhanced IL-1β-induced nitrite production and iNOS expression. Our results suggest that the LOX pathway, possibly including 12-LOX, is involved in the increase in IL-1β-induced nitrite production. Recently, a possible role of 12-HETE on salitylate-mediated nitrite production has been suggested in VSMCs (32) . Baicalein have been shown to inhibit LPS-induced nitrite production and iNOS protein expression in RAW 264.7 macrophages (33). In our study, baicalein produced a significant decrease in nitrite levels, while it did not affect iNOS protein expression. It could be argued that baicalein inhibits iNOS activity without affecting protein expression in VSMCs.
In contrast to baicalein, the selective 5-LOX inhibitor REV5901 did not affect IL-1β-induced nitrite or iNOS levels (data not shown). Exogenous eicosanoids, i.e., 5(S)-HETE, 12(R)-HETE, and 15(S)-HETE, did not enhance the IL-1β-induced nitrite production (Fig. 4) . 12(R)-HETE also failed to enhance the IL-1β-induced iNOS protein expression. Therefore, 5-LOX, 15-LOX, or 12(R)-LOX may not play a major role in the induction of NO production in rat VSMCs.
AA is released by PLA2. Among the several known groups of PLA2s, only sPLA2 and cytosolic PLA2 (cPLA2) are able to release AA from phospholipids (34) . As shown in Fig. 2 , the sPLA2 inhibitor ONO-RS-082 reduced both IL-1β-stimulated nitrite accumulation and iNOS protein synthesis. The cPLA2 inhibitor AACOCF3 also reduced the slight but significant decrease in stimulated nitrite accumulation and iNOS protein synthesis. These results suggest that both sPLA2 and cPLA2 are involved in the regulation of nitrite production and iNOS expression in VSMCs. In this study, sPLA2 inhibition by ONO-RS-082 was more effective than cPLA2 inhibition by AACOCF3. Thus the sPLA2 pathway may be predominantly involved in IL-1β regulation of nitrite production and iNOS expression in VSMCs. This is the first evidence demonstrating that sPLA2 participates in the regulation of nitrite production and iNOS expression in IL-1β-stimulated VSMCs.
COX-2 is also induced by cytokines in many types of cells (35) . The COX inhibitor indomethacin has been shown to enhance cytokine-induced nitrite production in mesangial cells, and this effect was reversed by the replacement of PGE2, which is the main product of the COX pathway (36) . This previous study thus indicated the possible involvement of prostaglandin E2 (PGE2) in the negative regulation of nitrite production. In VSMCs, macrophages, and myocytes, however, indomethacin appeared to have no effect on the levels of nitrite production (25, 27, 37) . In the present study, the non-selective COX inhibitor indomethacin and the selective COX-2 inhibitor NS-398 did not affect IL-1β-stimulated nitrite or iNOS levels in VSMCs (Fig. 5) . These results suggest that COX products may not participate in the regulation of cytokine-stimulated NO production in VSMCs.
In conclusion, IL-1β induces LOX products, which are able to modulate IL-1β-stimulated NO production. Inhibition of LOX products may contribute to protection against tissue injury in vascular pathologies involving an inflammatory response, such as atherosclerosis.
